Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAPEMBRO: pembrolizumab plus ataluren in metastatic colorectal, endometrial, stomach, and small bowel mismatch repair-defined cancers
NL-OMON55845Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and ataluren in colorectal cancer (CRC), endometrial cancer (EC), gastric cancer (GC) and 1 more, sponsored by Amsterdam University Medical Center. Primary endpoints: Immune-related progression-free survival rate at 21 weeks and Immune-related objective response rate at 30 weeks. Started Aug 2019; status: recruiting.
02
Drugs
pembrolizumabataluren
03
Conditions
colorectal cancer (CRC)endometrial cancer (EC)gastric cancer (GC)small bowel cancer
Beyond the preview
Go deeper on NL-OMON55845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55845.